Advertisement

Infection

, Volume 45, Issue 6, pp 801–809 | Cite as

Community-acquired lower respiratory tract infections in HIV-infected patients on antiretroviral therapy: predictors in a contemporary cohort study

  • Cristiane C. LamasEmail author
  • Lara E. Coelho
  • Beatriz J. Grinsztejn
  • Valdilea G. Veloso
Original Paper

Abstract

Community-acquired pneumonia represents the most frequent bacterial infection in patients with HIV/AIDS.

Purpose

We aimed to assess variables associated with lower respiratory tract infection (LRTI) among HIV-infected adults using ART.

Methods

A cohort study of HIV-infected patients aged ≥18 years, enrolled from 2000 to 2015, on ART for at least 60 days, with primary outcome as the 1st episode of LRTI during follow-up. The independent variables included were sex at birth, age, race/skin color, educational level, tobacco smoking, alcohol use, cocaine use, diabetes mellitus, CD4 count, HIV viral load, influenza and pneumococcal vaccination. Extended Cox proportional hazards models accounting for time-updated variables were fitted to assess LRTI predictors.

Results

2669 patients were included; median follow-up was 3.9 years per patient. LRTI was diagnosed in 384 patients; incidence rate was 30.7/1000 PY. In the unadjusted Cox extended models, non-white race [crude hazard ratio (cHR) 1.28, p = 0.020], cocaine use (cHR 2.01, p < 0.001), tobacco smoking (cHR 1.34, p value 0.007), and HIV viral load ≥400 copies/mL (cHR 3.40, p < 0.001) increased the risk of LRTI. Lower risk of LRTI was seen with higher educational level (cHR 0.61, p < 0.001), rise in CD4 counts (cHR 0.81, p < 0.001, per 100 cells/mm3 increase), influenza (cHR 0.60, p = 0.002) and pneumococcal vaccination (cHR 0.57, p < 0.001). In the adjusted model, aHR for CD4 count was 0.86, for cocaine use 1.47 and for viral load ≥400 copies 2.20.

Conclusions

LRTI has a high incidence in HIV-infected adults using ART. Higher CD4 counts and undetectable viral loads were protective, as were pneumococcal and influenza vaccines.

Keywords

Community-acquired pneumonia HIV AIDS Antiretroviral therapy Vaccination 

Notes

Acknowledgements

We thank Dr. Michael Bruce Macrae for his assistance with language editing. This work was supported in part by the NIH-funded Caribbean, Central and South America network for HIV epidemiology (CCASAnet), a member cohort of the International Epidemiologic Databases to Evaluate AIDS (leDEA) (U01AI069923). This award is funded by the following institutes: Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Cancer Institute (NCI), National Institute Of Allergy And Infectious Diseases (NIAID), National Institute Of Mental Health (NIMH), and the Office Of The Director, National Institutes Of Health (OD).”.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Supplementary material

15010_2017_1041_MOESM1_ESM.docx (21 kb)
Supplementary material 1 (DOCX 20 kb)
15010_2017_1041_MOESM2_ESM.docx (19 kb)
Supplementary material 2 (DOCX 19 kb)

References

  1. 1.
    Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.CrossRefPubMedGoogle Scholar
  2. 2.
    Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68:1057–65.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Mullerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106:1124–33.CrossRefPubMedGoogle Scholar
  4. 4.
    Kornum JB, Due KM, Norgaard M, et al. Alcohol drinking and risk of subsequent hospitalisation with pneumonia. Eur Respir J. 2012;39:149–55.CrossRefPubMedGoogle Scholar
  5. 5.
    Schwarcz L, Chen MJ, Vittinghoff E, Hsu L, Schwarcz S. Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance. Aids. 2013;27:597–605.CrossRefPubMedGoogle Scholar
  6. 6.
    Lima VD, Lourenço L, Yip B, Hogg RS, Phillips P, Montaner JS. AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study. Lancet HIV. 2015;2:e92–7.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Coelho L, Cardoso SW, Amancio RT, et al. Trends in AIDS-defining opportunistic illnesses incidence over 25 years in Rio de Janeiro, Brazil. PLoS One. 2014;9:e98666.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Søgaard OS, Reekie J, Ristola M, et al. Severe bacterial non-aids infections in HIV-positive persons: incidence rates and risk factors. J Infect. 2013;66:439–46.CrossRefPubMedGoogle Scholar
  9. 9.
    Ribeiro SR, Luz PM, Campos DP, et al. Incidence and determinants of severe morbidity among HIV-infected patients from Rio de Janeiro, Brazil, 2000–2010. Antivir Ther. 2014;19:387–97.CrossRefPubMedGoogle Scholar
  10. 10.
    Grinsztejn B, Luz PM, Pacheco AG, et al. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One. 2013;8:e59768.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ford N, Shubber Z, Meintjes G, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV. 2015;2:e438–44.CrossRefPubMedGoogle Scholar
  12. 12.
    Lewden C, Drabo YJ, Zannou DM, et al. Disease patterns and causes of death of hospitalized HIV-positive adults in West Africa: a multicountry survey in the antiretroviral treatment era. J Int AIDS Soc. 2014;7:18797.Google Scholar
  13. 13.
    Kim JH, Psevdos G Jr, Gonzalez E, Singh S, Kilayko MC, Sharp V. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART). Infection. 2013;41:545–51.CrossRefPubMedGoogle Scholar
  14. 14.
    Feikin DR, Feldman C, Schuchat A, et al. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis. 2004;4:445–55.CrossRefPubMedGoogle Scholar
  15. 15.
    Báez-Saldaña R, Villafuerte-García A, Cruz-Hervert P, et al. Association between highly active antiretroviral therapy and type of infectious respiratory disease and all-cause in-hospital mortality in patients with HIV/AIDS: a case series. PLoS One. 2015;10:e0138115.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Sogaard OS, Lohse N, Gerstoft J, et al. Hospitalization for pneumonia among individuals with and without HIV infection, 1995–2007: a Danish population-based, nationwide cohort study. Clin Infect Dis. 2008;47:1345–53.CrossRefPubMedGoogle Scholar
  17. 17.
    BRASIL. Ministério da Saúde/Secretaria de Vigilância em Saúde. Departamento de DST, Aids e Hepatites Virais. Protocolo clínico e diretrizes terapêuticas para manejo da infecção pelo HIV em adultos. Brasília 2013. 2015.Google Scholar
  18. 18.
    Benard A, Mercie P, Alioum A, et al. Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000–2007. PLoS ONE. 2010;5:e8896.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Crothers K, Huang L, Goulet JL, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011;183:388–95.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Curran A, Falco V, Crespo M, et al. Bacterial pneumonia in HIV-infected patients: use of the pneumonia severity index and impact of current management on incidence, aetiology and outcome. HIV Med. 2008;9:609–15.CrossRefPubMedGoogle Scholar
  21. 21.
    Kohli R, Lo Y, Homel P, Flanigan TP, Gardner LI, Howard AA, et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis. 2006;43:90e8.CrossRefGoogle Scholar
  22. 22.
    Izquierdo C, Oviedo M, Ruiz L, Sintes X, Vera I, Nebot M, et al. Influence of socioeconomic status on community-acquired pneumonia outcomes in elderly patients requiring hospitalization: a multicenter observational study. BMC Public Health. 2010;15:421.CrossRefGoogle Scholar
  23. 23.
    Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors for re-hospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis. 2008;46:550–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Stelianides S, Golmard JL, Carbon C, Fantin B. Influence of socioeconomic status on features and outcome of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1999;18:704–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Baldwin GC, Tashkin DP, Buckley DM, Park AN, Dubinett SM, Roth MD. Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am J Respir Crit Care Med. 1997;156:1606–13.CrossRefPubMedGoogle Scholar
  26. 26.
    Caiaffa WT, Vlahov D, Graham NM, et al. Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-sero-positive injection drug users. Am J Respir Crit Care Med. 1994;150:1493–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Tyagi M, Weber J, Bukrinsky M, Simon GL. The effects of cocaine on HIV transcription. J Neurovirol. 2016;22:261–74.CrossRefPubMedGoogle Scholar
  28. 28.
    Cook JA. Associations between use of crack cocaine and HIV-1 disease progression: research findings and implications for mother-to-infant transmission. Life Sci. 2011;88:931–9.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Nacher M, Adenis A, Hanf M, et al. Crack cocaine use increases the incidence of AIDS-defining events in French Guiana. AIDS. 2009;23:2223–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Centers for Disease Control. (CDC). Recommendations of the Immunizations Practices Advisory Committee: pneumococcal polysaccharide vaccine. MMWR. 1989;38:73–6.Google Scholar
  31. 31.
    Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990–2003. AIDS (London, England). 2006;20:437e44.CrossRefGoogle Scholar
  32. 32.
    Pedersen R, Lohse N, Ostergaard L, Sogaard O. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med. 2011;12:323e33.CrossRefGoogle Scholar
  33. 33.
    Beck CR, McKenzie BC, Hashim AB, Harris RC, University of Nottingha1m Influenza and the Immuno-Compromised (UNIIC) Study Group, Nguyen-Van-Tam JS. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis. 2012;206:1250–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Cristiane C. Lamas
    • 1
    • 2
    Email author
  • Lara E. Coelho
    • 1
  • Beatriz J. Grinsztejn
    • 1
  • Valdilea G. Veloso
    • 1
  1. 1.Instituto Nacional de Infectologia Evandro ChagasFundação Oswaldo CruzRio de JaneiroBrazil
  2. 2.Universidade do Grande RioRio de JaneiroBrazil

Personalised recommendations